MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg UlcersGlobeNewsWire • 02/12/25
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?Zacks Investment Research • 01/27/25
MediWound Reports Third Quarter 2024 Financial Results and Provides Company UpdateGlobeNewsWire • 11/26/24
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg UlcersGlobeNewsWire • 10/10/24
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal BurnsGlobeNewsWire • 08/15/24
MediWound Reports Second Quarter 2024 Financial Results and Provides Company UpdateGlobeNewsWire • 08/14/24
MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 08/07/24
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)GlobeNewsWire • 08/05/24
Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 07/31/24
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg UlcersGlobeNewsWire • 07/29/24
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator ProgramGlobeNewsWire • 07/16/24
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound LtdPRNewsWire • 07/15/24
MediWound Reports First Quarter 2024 Financial Results and Provides Company UpdateGlobeNewsWire • 05/29/24
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care ConferencesGlobeNewsWire • 04/25/24
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?Zacks Investment Research • 04/17/24